2024
The survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer
Johnson K, Ni A, Quiroga D, Pariser A, Sudheendra P, Williams N, Sardesai S, Cherian M, Stover D, Gatti-Mays M, Ramaswamy B, Lustberg M, Jhawar S, Skoracki R, Wesolowski R. The survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer. Npj Breast Cancer 2024, 10: 49. PMID: 38898072, PMCID: PMC11187074, DOI: 10.1038/s41523-024-00652-4.Peer-Reviewed Original ResearchInvasive disease-free survivalHER2+ breast cancerAdjuvant trastuzumabOverall survivalLocoregional therapyUnivariate analysisBreast cancerBenefit of adjuvant trastuzumabBenefits of adjuvant systemic therapyMulti-institutional retrospective analysisAdjuvant systemic therapyCompare survival outcomesDisease-free survivalTrastuzumab monotherapyNode-negativeSystemic therapyCombination therapySurvival benefitStatistically significant improvementSurvival outcomesRetrospective analysisMultivariate analysisPrimary outcomeTrastuzumabTherapy
2023
Stereotactic Radiosurgery for Women Older than 65 with Breast Cancer Brain Metastases
Upadhyay R, Klamer B, Perlow H, White J, Bazan J, Jhawar S, Blakaj D, Grecula J, Arnett A, Mestres-Villanueva M, Healy E, Thomas E, Chakravarti A, Raval R, Lustberg M, Williams N, Palmer J, Beyer S. Stereotactic Radiosurgery for Women Older than 65 with Breast Cancer Brain Metastases. Cancers 2023, 16: 137. PMID: 38201564, PMCID: PMC10778270, DOI: 10.3390/cancers16010137.Peer-Reviewed Original ResearchIntracranial progression-free survivalProgression-free survivalBreast cancer patientsBrain metastasesOverall survivalYounger patientsCancer patientsRadiation necrosisOlder womenOlder patientsPositive diseaseSystemic therapyMultivariable analysisTreatment patternsBiopsy-proven breast cancer patientsCox proportional hazards regression methodsIncidence of BMOlder breast cancer patientsSingle-institutional retrospective reviewTreatment-related adverse eventsAge groupsBreast cancer brain metastasesMetastatic breast cancer patientsWorse progression-free survivalProportional hazards regression methods
2022
Right Sizing Systemic Therapy for Patients with Breast Cancer. Where are we Today?
Williams N, Grimm M, Gast K, Lustberg M. Right Sizing Systemic Therapy for Patients with Breast Cancer. Where are we Today? Current Breast Cancer Reports 2022, 14: 142-152. DOI: 10.1007/s12609-022-00463-1.Peer-Reviewed Original ResearchEarly-stage breast cancerBreast cancerSystemic therapyClinical outcomesER-positive breast cancerTriple-negative breast cancerBreast cancer supportRobust clinical outcomesOptimized clinical outcomesQuality of lifePersonalized medicine approachNeoadjuvant regimensAdditional therapyEndocrine therapySelect patientsClinical trialsBest therapyPrognostic biomarkerPatientsCancer supportTherapyMedicine approachCancerRoutine useGenomic testing
2010
Epigenetic Therapy in Breast Cancer
Lustberg M, Ramaswamy B. Epigenetic Therapy in Breast Cancer. Current Breast Cancer Reports 2010, 3: 34-43. PMID: 23097683, PMCID: PMC3477864, DOI: 10.1007/s12609-010-0034-0.Peer-Reviewed Original ResearchEpigenetic changesHistone deacetylase inhibitorsMajor epigenetic changesNucleosome remodelingHistone modificationsEpigenetic regulationEpigenetic mechanismsDNA methylationGene sequencesEpigenetic therapyGene expressionDemethylating agentDeacetylase inhibitorsMultistep processBreast cancerEpigeneticsBreast carcinogenesisGenesMethylationSystemic therapyClinical trialsEffective therapyReversible processRegulationSingle agent